At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Subscribe To Our Newsletter & Stay Updated
